uniQure to file accelerated-approval BLA for Huntington’s gene therapy AMT-130 in Q3 2026 after FDA agrees 3-year Phase I/II data can support filing
https://finviz.com/stock?t=QURE&p=d
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.